But with GLP-1 drugs, she said, “everyone is kind of iterating in real time.” Here’s what we’ve learned in the process. At ...

A lifestyle program that includes low-glycemic index Mediterranean diet plus daily brisk walking and vitamin D ...

The Greenhouse, Northern Nevada's first dual-specialty residential treatment center for eating disorders and OCD, opens July ...

More than 1,300 verified clients have rated the Pompa Program on Trustpilot, with an average of 4.7 out of 5 stars — a reflection of the real-world outcomes participants are experiencing. · ...

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 pounds, in a late-stage clinical trial, the drugmaker said in a news ...

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...

A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than ...

The next generation of glucagonlike peptide 1 (GLP-1) weight-loss drugs has taken another step forward to U.S. Food and Drug Administration approval. In new clinical trial results from the ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

MEDVi is a telehealth platform offering GLP-1 weight loss medications, including both FDA-approved and compounded versions. Monthly costs vary, with compounded medications starting at $179 and ...

What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss. By Mark Miller Millions of older Americans may have access for the first time to obesity drugs ...